End O' The Line Revisited: Moving on from nitric oxide to CGRP  by De Mey, Jo G.R. & Vanhoutte, Paul M.
Life Sciences 118 (2014) 120–128
Contents lists available at ScienceDirect
Life Sciences
j ourna l homepage: www.e lsev ie r .com/ locate / l i fesc ieMinireviewEnd O' The Line Revisited: Moving on from nitric oxide to CGRPJo G.R. De Mey a,b, Paul M. Vanhoutte a,c,⁎
a Institute of Molecular Medicine, University of South Denmark, Odense, Denmark
b Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands
c Department of Pharmacology and Pharmacy and State Key Laboratory for Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong, China⁎ Corresponding author at: Department of Pharmacolo
E-mail address: vanhoutt@hku.hk (P.M. Vanhoutte).
http://dx.doi.org/10.1016/j.lfs.2014.04.012
0024-3205/© 2014 Elsevier Inc. Open access under CC BYa b s t r a c ta r t i c l e i n f oArticle history:
Received 15 November 2013
Accepted 5 April 2014
Available online 18 April 2014
Keywords:
Arterial blood pressure
Calcitonin gene related peptide
Endothelin-1
Endothelium
ETA receptors
ETB receptors
Exocytosis
Nitric oxide
Nitric oxide synthase
Oxidative stress
Vascular toneWhen endothelin-1(ET-1) was discovered it was hailed as the prototypical endothelium-derived contracting
factor (EDCF). However, over the years little evidence emerged convincingly demonstrating that the peptide
actually contributes to moment-to-moment changes in vascular tone elicited by endothelial cells. This has
been attributed to the profound inhibitory effect of nitric oxide (NO) on both the production (by the endotheli-
um) and the action (on vascular smoothmuscle) of ET-1. Hence, the peptide is likely to initiate acute changes in
vascular diameter only under extreme conditions of endothelial dysfunction when the NO bioavailability is
considerably reduced if not absent. The present essay discusses whether or not this concept should be revised,
in particular in view of the potent inhibitory effect exerted by calcitonin gene related peptide (CGRP) released
from sensorimotor nerves on vasoconstrictor responses to ET-1.
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Thirty years ago, we reported that endothelial cells can generate
vasoconstrictor signals for the underlying vascular smooth muscle
cells (De Mey and Vanhoutte, 1982, 1983). Many resulting moment-
to-moment changes in tone of isolated blood vessels can be explained
by the production of endothelium-derived vasoconstrictor prostanoids
or oxygen derived free radicals reducing the bioavailability of nitric
oxide (NO) (see Vanhoutte, 2011, 2013). However, studies with
cultured endothelial cells demonstrated the production of vasoconstric-
tor peptides (Hickey et al., 1985; Gillespie et al., 1986; O’Brien et al.,
1987), identiﬁed as endothelins, in particular endothelin-1 (ET-1), by
Yanagisawa and colleagues in 1988 (Yanagisawa et al., 1988). Despite
its crucial role in embryogenesis (Kurihara et al., 1994; Vanhoutte,
1994), the evidence supporting a major role of ET-1 in moment-
to-moment changes in vascular diameter did not seem overwhelming
(Vanhoutte, 1993). It soon became clear not only that NO is a powerful
functional antagonist of the action of ET-1 (Miller et al., 1989) and
reduces the production of the peptide (Boulanger and Lüscher, 1990),
but also that the latter can evoke the release of the former (Schini
et al., 1991) (Fig. 1). Hence, the Ying and Yang concept (“Say NO to
ET”) emerged that, in the peripheral circulation, as long as the endothe-
lial cells generate enough NO ET-1 is not likely to play a major role in
vascular homeostasis (Vanhoutte, 2000; Feletou et al., 2008, 2012).
Only when the protective function of the endothelial cells fails, at the
end of the line, would ET-1 raise its ugly head and contribute to the ter-
minal signs of vascular disease. It is beyond the scope of the present
essay to provide an exhaustive analysis of the literature concerning
ET-1 which is available in a number of review articles to which the
reader is referred (Schini and Vanhoutte, 1991; Rubanyi and Polokoff,
1994; Miyauchi and Masaki, 1999; Barton et al., 2003; Thorin and
Clozel, 2010; Lekontseva et al., 2010; Nguyen et al., 2010; Watts,
2010; Bourque et al., 2011; Dashwood and Abraham, 2011; Ergul,
2011; Rodríguez-Pascual et al., 2011; Rubanyi, 2011; Mazzuca and
Khalil, 2012; Pernow et al., 2012; Vignon-Zellweger et al., 2012; Jain,
2013). We will rather survey some recent ﬁndings and consider
whether or not the possibly too naïve concept outlined above should
be revised. In particular, we will examine whether or not braking
systems exist beyond endothelium-derived NO and consider whetherFig. 1. Release and actions of endothelin-1 (ET-1) in the vascular wall. AA: arachidonic
acid; cAMP = cyclic AMP; cGMP = cyclic GMP; COX = cyclooxygenases; EDHF =
endothelium-derived hyperpolarizing factor; ETA and ETB = endothelin-receptors; NO =
nitric oxide; NOS = nitric oxide synthase; PGI2 = prostacyclin; R = cell membrane
receptor. Dashes lines = inhibition. (Redrawn from Feletou et al., 2008).or not vascular ET-1 truly contributes to daily changes in systemic
vasomotor tone. This article is not a full review of the literature that is
available on the subject but rather the expression of personal views
that focuses a great deal on the authors’ own work.
The braking systems
Say NO to ET
The proposal that a sufﬁcient production of NOprevents amajor role
for ET-1 in the blood vessel wall (Fig. 1; Vanhoutte, 2000; Feletou et al.,
2008, 2012) is based on a number of experimental ﬁndings: a] the
cellular co-localization of endothelial NO synthase (eNOS) and ET-1
(Aliev et al., 1996; Loesch and Burnstock, 1996; Rubino et al., 1999;
Saitongdee et al., 1999); b] the reduction by endogenous and exogenous
NO of the expression and the production of ET-1 (Boulanger and
Lüscher, 1990; Brunner et al., 1995; Dun et al., 1999; Mitsutomi et al.,
1999), but its augmented expression by uncoupling (Oelze et al.,
2012) or reduced Akt-dependent activation (Li et al., 2013) of
eNOS; c] the abrupt reduction by endogenous and exogenous NO
of the sustained vasoconstrictor response to the peptide (Miller
et al., 1989; Lillestol et al., 1998; Baylis, 1999; Chen et al., 2003),
both in cyclic-GMP dependent (Bouallegue et al., 2007) and inde-
pendent (Goligorsky et al., 1994) ways; and d] the activation by
ET-1 of endothelial ETB receptors linked to NO production (Schini
et al., 1991; Magazine and Srivastavaj, 1996; Feger et al., 1997;
Gratton et al., 1997; Kakoki et al., 1999) which offsets, the genera-
tion of the peptide and curtails its vasoconstrictor effect at least in
some vascular beds.
One of the strongest arguments to accept the modulator role of NO
on the production/action of ET-1 is provided by the repeated observa-
tions in several species that ET receptor antagonists prevent or reverse
the increases in arterial blood pressure and/or the local vasoconstric-
tions caused by NOS inhibitors (Richard et al., 1995; Banting et al.,
1996; Gardiner et al., 1996; Filep, 1997; Gratton et al., 1997; Fink
et al., 1998; Pollock et al., 1998; Thorin et al., 1998; Wang et al., 1998;
Qiu and Baylis, 1999). This is particularly true in the kidney (Gardiner
et al., 1996; Pollock et al., 1998; Baylis, 1999; Qiu and Baylis, 1999).
Thus, in rats, the acute administration of the NO synthase (NOS)
inhibitor L-NAME causes a modest increase in circulating ET-1 levels
and a pressor response that is prevented by a non-selective ET recep-
tor antagonist and the selective ETA-antagonist BQ123, while these
compounds did not modify arterial blood pressure in the absence
of NOS blockade (Richard et al., 1995; Banting et al., 1996). The
blood pressure of eNOS-deﬁcient mice is markedly increased when
they are intercrossed with ET-1 transgenic mice (Quaschning et al.,
2007). These observations are all compatible with the “Say NO to
ET” view. Actually, certain effects of ET-1 can only be observed in
the absence of NO. In rat mesenteric resistance arteries, a contribu-
tion of endogenous ET-1 to vasomotor responses in terms of smooth
muscle-driven gap-junctional communication with the endothelium
is seen only during NO synthase inhibition (Hilgers and De Mey,
2009).
It seems fair to say that the concept that NO normally preempts a
vascular role for ET-1 has withstood the test of time and even gained
further believers (Thorin and Clozel, 2010; Bourque et al., 2011). The
dual action of nitric oxide on the release and the action of ET-1 provides
a satisfactory explanation for the minor contribution of the peptide in
local vasomotor conditions under normal circumstances. However, as
the endothelium ages and/or regenerates (Vanhoutte et al., 2009), the
buffering action of NO on the production and the inhibition it exerts of
the constrictor and growth promoting effects of ET-1 disappear
allowing the peptide to contribute (more) to vascular abnormalities in
the terminal stages of cardiovascular disease (Feletou et al., 2012).
Actually, as endothelial function declines with a reduced release of
NO, any locally produced ET-1 could in an autocrinemanner precipitate
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prostanoids (Auch-Schwelk and Vanhoutte, 1992; Taddei and
Vanhoutte, 1993; Park et al., 1999; Zhou et al., 2006) and thus exac-
erbate endothelial dysfunction (Vanhoutte, 2011). Several ﬁndings
seem to strengthen this “Say NO to ET as long as possible” view. In
aged rats, endothelial release of ET-1 is more marked (Goel et al.,
2010) and the blood pressure lowering effect of ETA-antagonists
more prominent (Bourque et al., 2013) than in young animals
where it is often not even statistically signiﬁcant. Pre-eclampsia, is
characterized by increased levels of sFlt-1, [a circulating scavenging
receptor for the endothelial survival factor vascular endothelial
growth factor (VEGF)] and an activated endothelin-system
(George and Granger, 2011; Tal, 2012). Administration of sFlt-1 or
inhibitors of VEGF receptor tyrosine kinase to rats or cancer pa-
tients, causes hypertension that can be reduced by ETA-antagonists
(Kappers et al., 2010, 2011; Lankhorst et al., 2014). Mice in which
ageing is accelerated due to deﬁcient telomerase activity develop
hypertension because of an excess of ET-1 production (Perez-
Rivero et al., 2006).
Caveats
The original vision of the vascular wall (Fig. 1) with ET-1 originating
only in the endotheliummay need to be revised. An ETA-antagonist can
cause relaxation in arteries without endothelium suggesting the
production of ET-1 by other cell types (Vedernikov et al., 1993).
Likewise, in smooth muscle cell selective ETA-receptor deﬁcient
(Stuart et al., 2013) and in endothelial cell-selective ET-1 deﬁcient
(Kisanuki et al., 2010) mice, arterial blood pressure is reduced to the
same extent. Surprisingly, in the latter an acute blood pressure
lowering effect of ETA-antagonism is maintained indicating that
ET-1 is not only supplied by the endothelium to the arterial wall
(Kisanuki et al., 2010). Also, endogenous vasoconstrictor prosta-
glandins that can contribute to the arterial contractile response of
ETA-stimulation may be derived from sources other than the endo-
thelium (Zhou et al., 2006).
In vitro, NO donors reduce ET-1 induced vasoconstrictions and
vasospasm initiated by the peptide but often fail to terminate them.
This anti-endothelinergic effect of NO is explained best by a non-
selective but potent functional antagonism which is shared by hyper-
polarizing agents, stimuli increasing cyclic AMP levels and calcium
channel blockers (Meens et al., 2009, 2010, 2011). The acute ETB-
mediated feedback loop involving endothelium-dependent vasodilata-
tion (Schini et al., 1991; Magazine and Srivastavaj, 1996; Gratton
et al., 1997) is less prominent than originally proposed. Indeed, in the
rat bigET-1 raises arterial blood pressure but does not initially reduce
it (Meens et al., 2010). By contrast, ET-1 causes an initial, very transient
depressor response followed by a long-lasting increase in arterial blood
pressure (Yanagisawa et al., 1988; Meens et al., 2011). The initial dip in
arterial blood pressure is absent but the subsequent pressor response is
not modiﬁed in rescued ETB-deﬁcient rats (Gariepy et al., 2000). A least
in some isolated blood vessels, the presence of immunoreactive
endothelial ETB-receptors can be demonstrated but ETB-selective
agonists fail to induce relaxation (unlike the endothelium-dependent
vasodilator acetylcholine) and the sensitivity and maximal contractile
responses to ET-1 are not modiﬁed by ETB-antagonists, NOS inhibitors
or removal of the endothelium (Meens et al., 2009, 2010; Compeer
et al., 2012). In the same blood vessels, advanced vital molecular
imaging techniques, demonstrate that ﬂuorescently labeled ET-1 and
ﬂuorescently labeled linear ET-1 (an ETB-selective agonist) bind to the
vascular smooth muscle but not the endothelial cells (Meens et al.,
2010). Presence of ETB-receptors on the nuclear membrane but not
the cell membrane may explain these discrepancies (Deliu et al., 2012;
Merlen et al., 2013). However, the measurements of circulating levels
of ET-1 after systemic administration of ETB-antagonists and several
animal models of ETB-receptor deﬁciency indicate an important role ofendothelial ETB-receptors, in particular in the pulmonary circulation,
in scavenging the peptide from the blood stream (for review see
Mazzuca and Khalil, 2012).
By contrast to acute NOS inhibition (see 2.1),ﬁndings during chronic
L-NAME administration to rats are not so clear. It induces chronic hyper-
tension with increased levels of ET-1 in the serum and in the aorta
(Edwards et al., 1996; Pollock et al., 1998; D’Amours et al., 1999). It is
not accompanied by altered expression of preproET-1 in either the
aorta or mesenteric resistance arteries (Sventek et al., 1997) although
increases in preproET-1 mRNA and ET-1 peptide levels are observed in
preglomerular arterioles after four weeks of treatment with the NOS
inhibitor (Tharaux et al., 1999). The hypertension is not modiﬁed by
bosentan (Moreau et al., 1997; Tharaux et al., 1999) or by the ETA-
antagonist A127722 although these two drugs inhibit the accom-
panying renal damage (Tharaux et al., 1999; Boffa et al., 2001). The
ET-receptor antagonists do not improve endothelium-dependent
relaxations in either resistance arteries or the aorta and actually
exacerbate prostanoid-mediated, endothelium-dependent contractions
(Moreau et al., 1997). By contrast to the rat, in guinea pigs, the chronic
administration of L-NAME causes a seven fold increase in plasma levels
of endothelins. No inhibition of endothelium-dependent vasodilatation
could be observed in this species and circulating levels of nitrite as
well as tissue levels of cGMP were increased, rather than decreased
(Miller et al., 1995). When multiple negative (feedback) regulating
mechanisms are available (see section C below), the blockade, failure
or deﬁciency of one of them can be compensated by up-regulation of
the others. Because this up-regulation can take time, redundancy may
have contributed to some of the different conclusions reached by
experiments involving acute and chronic blockade of NO synthases.
Several additional confounding factors may explain the different
conclusions from studies involving acute or chronic administration of
NOS inhibitors. L-NAME may have effects that are not exclusively due
to inhibition of NO production (Miller et al., 1996; Sventek et al.,
1997; Suda et al., 2002). The interaction between NO and ET-1 may
differ between modulation of acute vasomotor changes and impact on
long-term regulators of arterial blood pressure (e.g. renal function and
arterial remodeling).
Another source of confusion is the different use of ET antagonists
to probe the involvement of the peptide in the hypertension/
vasoconstriction caused by NOS inhibitors. In most acute studies,
antagonists are used to prevent while in most chronic studies they are
used to reverse. For acutely acting vasoconstrictors such as angiotensin
II or noradrenaline (norepinephrine) this should not make too much of
a difference. However, the basic pharmacology of ET-1 is peculiar. Since
its discovery, the peptide is known to be not only potent but also to
cause long-lasting effects in vitro and in vivo (Yanagisawa et al., 1988;
Meens et al., 2010, 2011). These are both a consequence of the tight
binding of the peptide especially to ETA-receptors (De Mey et al.,
2011). Once the peptide has associated with its receptors it dissociates
from them only slowly, i.e. the peptide has a long “residence time” on
its receptors. In radioligand binding experiments with cell membrane
fragments, the half live of ET-1/ETA-receptor complexes ranges from
seven to 77 hours (De Mey et al., 2011). Currently available low
molecular weight ET-receptor antagonists were discovered on the
basis of competition with ET-1 for binding to its receptors (Palmer,
2009). These compounds can not only prevent contractions to ET-1
but also reverse established contractions to the peptide at least to
some extent in vitro and in vivo (Clozel et al., 1993; Warner et al.,
1994; Roux et al., 1997; Pierre and Davenport, 1999; Böhm et al.,
2002). This curative reversing action can require a considerably higher
concentration of endothelin antagonist (Warner et al., 1994) differs
between vascular beds and between ET-1 and ET-2 initiated responses
in the systemic arterial tree of the rat (Meens et al., 2010, 2011;
De Mey et al., 2011; Compeer et al., 2013). These properties (agonist-
dependence, system-dependence and differences between the resting-
and the activated states of the receptors) suggest negative allosteric
Fig. 2. Impairment of endothelium-derived NO by arterial smooth muscle effects of
endothelin-1 (ET-1) mediated by endothelin ETA-receptors. Nox = NADPH oxidase;
sGC = soluble guanylyl cyclase; Xox = xanthine oxidase. Other abbreviations as in Fig. 1.
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et al., 2003; DeMey et al., 2011; Keov et al., 2011). Reports of antagonist
stimulated internalization of ETA receptors (Bhowmick et al., 1998;
Chiou et al., 2000) further support the complexity of the action of
endothelin receptor antagonists.
Is NO the only answer?
Endothelium-derived NO certainly is not the only weapon
against the powerful vasoconstrictor effect of ET-1. If only at the en-
dothelial level, the braking effect of NO would be reinforced by the
ability of ET-1 to induce endothelium-dependent hyperpolarization
(EDH) and/or to augment the endothelial production of prostacyclin
(Nakashima and Vanhoutte, 1993; Goodwin et al., 1998; Carrier
et al., 2007). Especially EDH-mediated vasodilatations are of partic-
ular importance in the microcirculation. The important role of scav-
enging of ET-1 by the (pulmonary) endothelium has already been
alluded to above. But beyond the endothelial cells, other control sys-
tems exist.
Homologous regulation
The amino acid sequence of ET-receptors is quite similar to that of
other type-A G protein coupled receptors like β-adrenoceptors and
angiotensin AT1-receptors (Masaki, 2004). The latter receptors display
homologous desensitization, homologous down-regulation and biased
signaling (Reiter et al., 2012). For example, during continuous exposure
to β-adrenergic agonists or angiotensin II the afﬁnity of the receptors
falls as a result of phosphorylation by G protein-coupled receptor
kinases (GRK). This recruits arrestin to agonist-activated receptors
which are thereby uncoupled from their G proteins and internalized
into the cells where they can continue to signal through alternative
pathways (Reiter et al., 2012). This contributes to a profound reduction
of the expression of receptor protein duringprolonged agonist exposure
(homologous down-regulation). Contractions in response to ETB-
stimulation are markedly up-regulated within hours in arteries main-
tained in organ culture outside of the body (Henriksson et al., 2003;
Eskesen and Edvinsson, 2006). ETA-receptors of arterial smoothmuscle,
on the other hand, escape at least partly from such homologous regula-
tion. In isolated rat mesenteric resistance arteries, ET-1 stimulates long-
lasting (several hours) contractions resulting from activation of
ETA-receptors on the vascular smooth muscle (Meens et al., 2010,
2011; Compeer et al., 2013). In smooth muscle cells isolated from
these arteries but maintaining a contractile phenotype, ET-1 causes a
transient and poorly reproducible ETA-receptor mediated increase in
the cytoplasmic concentrations of calcium ions and inositol triphos-
phate (Morris et al., 2010). GRK2 is responsible for this desensitization.
Agonist-stimulated human ETA- and ETB-receptors can recruit arrestins
(Maguire et al., 2012) and both types of receptors can be internalized
(Gregan et al., 2004). Furthermore, in several models characterized by
an up-regulated ET-1 system, a marked reduction of arterial ETA-
receptor protein has been observed (Molero et al., 2002; Zhou et al.,
2006; Quaschning et al., 2007). Still, ET-1 causes long-lasting ETA-
mediated vasoconstriction in such arteries. The observation that
the initiation and maintenance of ET-1 induced vasoconstriction
involve different signal-transduction pathways (Compeer et al., 2013)
reconciles part of these ﬁndings.
Oxidative stress
In addition to being a potent stimulus of vasoconstriction/
vasospasm, ET-1 is also a potent stimulator of oxidative stress. ETA-
receptor stimulation causes production of superoxide anions by
NADPH oxidase-dependent and –independent mechanisms (Li et al.,
2003; Callera et al., 2006; Viel et al., 2008). The kinetics of this pro-
oxidative effect (sustained or transient, maintained/long-lasting or
rapidly reversible) are less well understood than those of the contractile
response to the peptide. Yet, superoxide anions bind rapidly to NO toform peroxynitrite (ONOO−), a process involved in the reduced
bioavailability of endothelium-derived NO in many instances of
endothelial dysfunction and in addition adversely affect the activity of
soluble guanylyl l cyclase, one of the main targets of NO in the vascular
wall (Stasch et al., 2011). Thereby ET-1 can through the production of
superoxide anions silence its inhibition by endothelium-derived NO
(Fig. 2).
The terminator
Besides endothelium and vascular smoothmuscle, peripheral nerves
are potential sources of and targets for endothelin peptides (Wang and
Wang, 2004). The observation that in rat mesenteric resistance arteries,
endothelium-derived NO cannot terminate vasoconstrictions caused by
ET-1, prompted an investigation of the possible modulator role of
sensorimotor nerves located between tunica media and –adventitia
(Meens et al., 2009, 2010). ET-receptor proteins co-localized with the
sensorimotor neurotransmitter calcitonin gene-related peptide
(CGRP). Selective stimulation of these nerves not only inhibited but
also reversed and terminated ET-1 initiated contractions. These effects
were prevented by antagonists of CGRP-receptors and could be mim-
icked by exogenously applied CGRP. Two foton excitation microscopy
of the intra-arterial binding of ﬂuorescently labeled ET-1, demonstrated
that exogenous and endogenously released CGRP promotes the
dissociation of ET-1/ETA-receptor complexes on arterial smooth muscle
(Meens et al., 2010) (Fig. 3). CGRP can stimulate NO-mediated
endothelium-dependent vasodilatation and cAMP production by
adenylyl cyclase (Brain and Grant, 2004). However, termination of the
interaction between ET-1 and ETA-receptors and of the contraction
does not involveNOcAMP, butGproteinβγ subunit-mediated signaling
(Meens et al., 2012). Like the distribution of sensorimotor nerves, this
CGRP- /ETA-receptor crosstalk is not uniformly distributed over the rat
arterial tree with the cerebral and coronary vasculatures being notable
exceptions (Meens et al., 2011). It is, however, sufﬁciently widespread
to inﬂuence total peripheral vascular resistance and arterial blood
pressure responses to ET-1 and bigET-1 in vivo (Meens et al., 2011).
Contribution of endothelin-1 to systemic vasomotor tone
Although powerful mechanisms counteract the production and/or
the action of ET-1, the question of importance of course is whether or
Fig. 3. Peri-arterial sensorimotor nerves attenuate ETA-receptor mediated arterial smooth
muscle responses to ET-1. Calcitonin gene-related peptide (CGRP) released from sensori-
motor nerves functionally antagonizes ET-1 induced contractions via cyclic AMP and
promotes dissociation of ET-1/ETA-receptor complexes via G-protein βγ subunits. Note
that as indicated by the colored circles not only endothelial and smooth muscle cells,
but also sensorimotor nerve endings are equipped with endothelin receptors. Abbrevia-
tions are as in Fig. 1.
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to basal vasomotor tone. This may not always be the case.
Of mice…
Genetic manipulations
Gene deletion. Homozygous preproET-1 knock-out mice die at birth as a
result of the important role of the ET-axis in embryonic development
(Kurihara et al., 1994). Heterozygous preproET-1 knock-out mice are
viable and display a paradoxically elevated arterial blood pressure
attributed to a central nervous system depressor role of the peptide
(Kurihara et al., 1994).
Mice with endothelial-cell speciﬁc preproET-1 deﬁciency have a
lower arterial blood pressure than wild type mice (Anggrahini et al.,
2009; Kisanuki et al., 2010). They surprisingly display an unaltered
blood pressure lowering effect of the ETA-antagonist FR139317
(Kisanuki et al., 2010). This may indicate that in vivo endothelins from
other sources than the endothelium contribute to blood pressure, as is
the case in some isolated blood vessels (Vedernikov et al., 1993). In
heterozygous ETA+/− and ETB+/− knock-out mice, arterial blood pressure
is normal but the aortic ET-1 content reduced in the former only
(Rodriguiz et al., 2008). In mice with smooth muscle cell selective
ETA-receptor knock-out, arterial blood pressure is reduced to the same
extent as in endothelial cell-selective preproET1 knock-out animals
(Kisanuki et al., 2010; Stuart et al., 2013). In the latter, chronic treatment
with the ETA-antagonists ambrisentan and atrasentan did not cause an
additional reduction in mean arterial blood pressure (Stuart et al.,
2013).
Gene overexpression. In general, arterial blood pressure is basically
normal [exemplifying a rather mild basal cardiovascular phenotype] in
transgenic rodents with systemic ET-overexpression, which is in line
with endogenous physiological antagonisms [e.g. NO and CGRP] of the
vasoconstrictor action of ET-1.
In a ﬁrst human ET-1 transgenic mouse model, plasma ET-1 is
increased moderately and the renal content of the peptide transiently
augmented (Hocher et al., 1997). With aging these animals developrenal failure but no hypertension (Hocher et al., 1997). In other
human ET-1 transgenic mice, ET-1 levels were increased in plasma,
heart, kidney and aorta and renal injury developed with aging. Arterial
blood pressure was normal on a normal sodium diet but hypertension
developed during to sodium loading (Shindo et al., 2002). Likewise in
human ET-2 transgenic rats, plasma and renal endothelin levels are
increased, renal injury develops but arterial blood pressure is normal
if the sodium intake is not augmented (Hocher et al., 1996; Liefeldt
et al., 1999). These observations suggest the presence of physiological
counter-regulatory mechanisms inﬂuencing the expected pressor
effects of endothelin(s).
Endothelial cell-speciﬁc overexpression of human preproET-1
using a Tie-1 promotor resulted in increased ET-1 expression in the
endothelium of brain and pulmonary blood vessels, moderate increases
in circulating and pulmonary ET-1 levels, reduced endothelium-
dependent relaxations, reduced contractions to ET-1, and an increase
in mean arterial blood pressure that could be reduced by the ETA
antagonist BQ123 (Leung et al., 2004, 2011; Zhang et al., 2013). Another
approach of endothelial cell-speciﬁc overexpression of human
preproET-1 using Tie-2 resulted in larger increases in tissue and plasma
ET-1 levels, reduced endothelium-dependent vasodilatation but also
decreased contractions to the peptide, and caused remodeling of
resistance arteries and vascular inﬂammation in the absence of signiﬁ-
cant hypertension (Amiri et al., 2004, 2010); Javeshghani et al., 2013).
High salt intake in this model, worsened endothelial dysfunction and
unmasked a chronic hypertension which was inhibited at least partly
by the ETA antagonist atrasentan and the mixed ETA/ETB antagonist
bosentan, but not the ETB antagonist A-192621 (Amiri et al., 2010).
Pharmacological approaches
Exogenous endothelins. In rats, chronic infusion of ET-1 did not inﬂuence
blood pressure if sodium intake was normal but caused hypertension
and vasoconstriction during sodium loading. The pressor response
was prevented by an angiotensin converting enzyme inhibitor but
was not accompanied by an increase in plasma angiotensin II levels
(Mortensen and Fink, 1992). In the same species, a longer chronic
(14 days) intravenous infusion of a smaller dose of ET-1 caused
increases in plasma renin activity and in angiotensin I and II levels,
accompanied by a sustained increase in mean arterial blood pressure
that was prevented by an angiotensin receptor blocker (Yao et al.,
2004). Chronic treatment of mice on a standard diet with 5 pmol/kg.
min ET-1 caused only a transient increase in blood pressure (Eskildsen
et al., 2013).
Endothelin receptor antagonists. In normal, quiescent rodents there may
be no noticeable impact at all of endothelin receptor antagonists on ar-
terial blood pressure (Wölkart et al., 2007; Allahdadi et al., 2008; Harris
et al., 2008; D'Angelo et al., 2010; Boesen and Pollock, 2010; Murphy
et al., 2010). However, ETA antagonists interfere with the redistribution
of blood ﬂow during exercise (Maeda et al., 2002). ETA, but in certain
cases also ETB receptor blockers can reduce arterial blood pressure
and/or improve vascular responsiveness in certain animal models of
sleep apnea (Allahdadi et al., 2008; Webster et al., 2013), behavorial
stress (D’Angelo et al., 2010), pre-eclampsia (Murphy et al., 2010),
hypertension (Iglarz et al., 2008; Banfor et al., 2009) ischemia-
reperfusion (Martinez-Revelles et al., 2012) or diabetes (Bender and
Klabunde, 2007; Iglarz et al., 2008; Harris et al., 2008). However, such
chronic effect on blood pressure may not necessarily be due to
vasodilatation stricto sensu but rather reﬂect reversal/prevention of
the trophic effects of the peptide (Maguire et al., 2002; Dao et al.,
2006; Takahashi, 2006; Iglarz et al., 2008). Certainly in terms of the ef-
fect of endogenous ET-1 on its receptors, as estimated by the inhibitory
effects of antagonists, and irrespective of the targeted cell, the level of
dietary intake of sodium is of paramount importance (Schneider et al.,
2007; Kopp et al., 2009).
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As for any putative mediator, to study the importance of a peptide
such as ET-1 in people is arduous. Circulating blood levels can be
measured, but their signiﬁcance has been questioned early on as they
do not necessarily correlate with changes in arterial blood pressure
(Goddard and Webb, 2000; Kappers et al., 2010). Theoretically, the
use of selective receptor-antagonists should permit to verify the poten-
tial contribution of the peptide to the regulation of arterial blood pres-
sure and/or local vasomotor tone, and dissociate between an impact
on endothelial (ETB) and vascular smooth muscle (ETA). Their inter-
pretation is complicated by the facts that ETB receptors can be located
on the latter (Deng et al., 1995; Halcox et al., 2007; Stauffer et al.,
2010; Rapoport and Zuccarello, 2012), and that ET-1 affects other cell
types involved locally or systemically in the control of vascular tone
(Kohan et al., 2012) and can bind tightly to its receptors (De Mey
et al., 2011). Despite these caveats, such studies indicate that, leaving
aside an obvious involvement of ET-1 in diseases such as pulmonary
hypertension (e.g. Galie et al., 2004; Böhm and Pernow, 2007; Rubin,
2012; Taguchi and Hattori, 2013), the vasomotor role of the peptide is
modulated by gender and the level of activity, is not necessarily obvious
in normal subjects (Cardillo et al., 2004; Stauffer et al., 2010;Weil et al.,
2011; Barrett-O’Keefe et al., 2013) but becomes progressively more
important with age (Van Guilder et al., 2007; Thijsen et al., 2007;
Stauffer et al., 2010), obesity and hypertension (Cardillo et al., 2004;
Weil et al., 2011;), insulin resistance/metabolic syndrome (Shemyakin
et al., 2006; Tesauro et al., 2009) and coronary disease (Halcox et al.,
2007). Again, the contribution of endogenous ET-1 is exacerbated by a
reduced NO bioavailability (Tesauro et al., 2009).
Moment-to-moment changes in vascular tone
Despite increasing evidence that ET-1 contributes to the chronic
maintenance of arterial blood pressure and peripheral resistance,
the question remains whether or not it can be considered as a true
endothelium-derived contracting factor (EDCF) causing moment-
to-moment changes in tone of the underlying vascular smooth muscle.
In the presence of a NOS inhibitor, insulin causes ET-1 mediated
vasoconstriction in skeletal muscle arterioles of the rat (Eringa et al.,
2002) and as mentioned above in rat mesenteric resistance arteries,
the peptide contributes to vasomotor responses to nerve stimulation
(Hilgers and De Mey, 2009). Direct evidence for the endothelial
exocytotic release of ET-1 leading to immediate changes in vascular
tone in vitro has been obtained in the aorta of aged rats, albeit in the
presence of a NOS inhibitor (Goel et al., 2010). In terms of acute changes
is vascular tone in vitro caused by endothelin receptor antagonists in the
absence of exogenous peptide, BQ-123 causes decreases in resting
tension and reduces hypoxic contractions in canine coronary arteries
without endothelium (and thus without NO) (Vedernikov et al.,
1993). Tezosentan reduces contractions to noradrenaline of isolated
aortae of diabetic, but not normal rats; the mRNA expression of pre-
pro-endothelin is increased and the endothelial production of NO
reduced in the former compared to the latter (Sartoretto et al., 2013).
These observations on isolated blood vessels obviously are in line with
the Say NO to ET concept. In the in vitro perfused normal rat heart,
non-selective and ETA-selective blockers increase coronary ﬂow, while
an ETB-selective antagonist does not (Goodwin et al., 1998). However,
in the perfused heart of diabetic rats, while BQ-123 does not affect
coronary resistance, the ETB-selective blocker BQ-788 reduces it
(Bender and Klabunde, 2007). In vivo, the acute changes in arterial
blood pressure (Allahdadi et al., 2008) or in blood ﬂow (de Beer et al.,
2008) caused by such antagonists are in favor of an “acute” role of ET-
1, as is the prevention of the increases in circulating levels of the peptide
and the accompanying surge in pressure caused by acute stress
(D’Angelo et al., 2010; Weil et al., 2011). In particular in humans, the
immediate increases in blood ﬂow and/or the improvement of thedilator responses to acetylcholine noted upon local administration of
ET receptor antagonists favor the interpretation that the peptide is
indeed an EDCF stricto sensu (Shemyakin et al., 2006; Weil et al.,
2011; Barrett-O’Keefe et al., 2013).
Conclusions
The low arterial blood pressure in smooth muscle-speciﬁc ETA-
receptor deﬁcient mice and in endothelial cell-speciﬁc ET-1 deﬁcient
mice, the vasodilator effect of ET-receptor antagonists infused into the
human forearm, and the detectable levels of endothelin peptides in
the blood (despite their short circulating half-lives) establish the
endothelin-axis as a signiﬁcant contributor to basal vasomotor tone.
Sources of endothelins contributing to the control of vascular tone are
not restricted to the endothelium. Vascular smooth muscle cells are
not the only target of the peptides in the blood vessel wall. The
endothelin-axis is tightly controlled at all levels by a variety of homo-
logous and heterologous negative feedback mechanisms. Among
these, there is little doubt that endothelial cells generate inhibitory
signals (mainly but not only NO)which acutely can curtail the vasocon-
strictor effect of ET-1. The control of the release/action of endothelins
goes beyond the endothelium, and this mere redundancy indirectly
emphasizes the importance of the peptides. The interactions of
endothelins with their receptors are long-lasting, and most of the ECE-
inhibitors and ET-receptor antagonists that have been developed are
not optimal to address the roles of the endothelin-axis in health and
disease because of the tightness of the ET/ET-receptor complexes.
Irrespective of the direct effect of the peptide on vascular cells, the
main role of ET-1 in vasomotor control could well be an indirect one
because of its major impact on kidney function and the dependency of
its vasoconstrictor/hypertensive effects on sodium intake (Gardiner
et al., 1996; Hocher et al., 1996; Sandgaard and Bie, 1996; Pollock
et al., 1998; Verhagen et al., 1998; Baylis, 1999; Pollock, 1999; Qiu and
Baylis, 1999; Tharaux et al., 1999; Boffa et al., 2001; Sasser et al., 2002;
Ge et al., 2007, 2008; Boesen and Pollock, 2010; Kohan et al., 2011;
Dhaun et al., 2012; Speed and Pollock, 2013). The regal route for
endothelin-lovers may well be the renal one!
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